[
    [
        {
            "time": "2023-10-01",
            "original_text": "Alnylam, Dicerna Join Forces to Take on Arrowhead",
            "features": {
                "keywords": [
                    "Alnylam",
                    "Dicerna",
                    "partnership",
                    "Arrowhead",
                    "biotech"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Alnylam, Dicerna Join Forces to Take on Arrowhead",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Rybelsus",
                    "EU approval",
                    "Type II Diabetes",
                    "pharmaceuticals"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Highlights From Fundsmith Equity Fund’s 2020 Investor Letter",
            "features": {
                "keywords": [
                    "Fundsmith",
                    "Equity Fund",
                    "investor letter",
                    "investment strategy"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "investment"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Highlights From Fundsmith Equity Fund’s 2020 Investor Letter",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]